DGAP-Adhoc

Merck KGaA: Merck to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry - Seite 2

are subject to a number of risks and uncertainties, many of which are
beyond control of Merck KGaA, Darmstadt, Germany, which could cause actual
results to differ materially from such statements.

Risks and uncertainties relating to the proposed transaction with
Sigma-Aldrich Corporation ('Sigma-Aldrich') include, but are not limited
to: the risk Sigma-Aldrich's shareholders do not approve the transaction;
uncertainties as to the timing of the transaction; the risk that regulatory
or other approvals required for the transaction are not obtained or are
obtained subject to conditions that are not anticipated; competitive
responses to the transaction; litigation relating to the transaction;
uncertainty of the expected financial performance of the combined company
following completion of the proposed transaction; the ability of Merck
KGaA, Darmstadt, Germany, to achieve the cost-savings and synergies
contemplated by the proposed transaction within the expected time frame;
the ability of Merck KGaA, Darmstadt, Germany, to promptly and effectively
integrate the businesses of Sigma-Aldrich and Merck KGaA, Darmstadt,
Germany; the effects of the business combination of Merck KGaA, Darmstadt,
Germany, and Sigma-Aldrich, including the combined company's future
financial condition, operating results, strategy and plans; the
implications of the proposed transaction on certain employee benefit plans
of Merck KGaA, Darmstadt, Germany, and Sigma-Aldrich; and disruption from
the proposed transaction making it more difficult to maintain relationships
with customers, employees or suppliers.

Additional risks and uncertainties include, but are not limited to: the
risks of more restrictive regulatory requirements regarding drug pricing,
reimbursement and approval; the risk of stricter regulations for the
manufacture, testing and marketing of products; the risk of destabilization
of political systems and the establishment of trade barriers; the risk of a
changing marketing environment for multiple sclerosis products in the
European Union; the risk of greater competitive pressure due to
biosimilars; the risks of research and development; the risks of
discontinuing development projects and regulatory approval of developed
medicines; the risk of a temporary ban on products/production facilities or
of non-registration of products due to non-compliance with quality
standards; the risk of an import ban on products to the United States due
to an FDA warning letter; the risks of dependency on suppliers; risks due